Hepatitis C and the renal transplant patient

Seminars in Dialysis

Volumn 9, Issue 1, 1996, Pages 39-46

  Rosen, Hugo R ^a   Friedman, Lawrence S ^b   Martin, Paul ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005853952     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139x.1996.tb00899.x     Document Type: Review

References (74)

1. Gross JB, Persing DH: Hepatitis C: Advances in diagnosis. Mayo Clinic Proc 70:296-297, 1995
2. Brechot C: Hepatitis C genetic variability: Clinical implications. Am J Gastroenterol 89(Suppl):S41-S47, 1994
3. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L: Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 14:381-388, 1991
4. Han JH, Shyamala V, Richman KH, Brauer MJ, Irvine B, Urdea MS, et al.: Characterization of the terminal regions of hepatitis C viral RNA: Identification of conserved sequences in the 5′ untranslated region and poly (A) tails and the 3′ end. Proc Natl Acad Sci USA 88:1711-1715, 1991
5. Martin P: Hepatic C genotypes: The key to pathogenicity? Ann Intern Med 122(3):227-228, 1995
6. Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin in Liver Dis 15:41-63, 1995
7. Esteban JI, Genesca J, Alter HJ: Hepatitis C: Molecular biology, pathgenesis, epidemiology, clinical features, and prevention. Prog Liver Dis X:252-282, 1992
8. Alberti A: Diagnosis of hepatitis C: Facts and perspectives. J Hepatol 12:279-282, 1991
9. Alter HJ: Descartes before the horse: I clone therefore I am: The hepatitis C virus in current perspective. Ann Intern Med 115:644-649, 1991
10. Alter HJ: New kit on the block: Evaluation of second generation assays for detection of antibody to the hepatitis C virus. Hepatology 15:130-136, 1992
11. Genesca J, Viladomiu L, Gonzalez A, Esteban JI, Lopez-Talaver JC, et al.: Second generation EIA evaluation of acute PT-NANBH. J Hepatol 13(Suppl 2):122-123, 1991
12. Lee SR, Francis B, Botsko E, Ball V, Paje E, Scholm P, et al.: Improved detection of antibodies to hepatitis C virus in volunteer blood donors using a second-generation HCV ELISA. Proceedings of the Third International Symposium on HCV. Strasbourg, September 1991:123
13. Bukh J, Wantzin P, Krogsgaard K, Knudsen, Purcell RH, Miller RH: High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 168:1343-1348, 1993
14. Hu K-Q, Vierling JM: Molecular diagnostic techniques for viral hepatitis. Gastroenterol Clin N Am 23:479-498, 1994
15. Hopf U, Moller B, Kuther D, Stmerowicz R, Loebeck H, Lutke-Handjery A, et al.: Long-term followup of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus. J Hepatol 10:69-76, 1990
16. DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ: Longterm clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 14:969-974, 1991
17. Perrillo RP: Antiviral agents in the treatment of chronic viral hepatitis. Prog Liver Dis X:283-309, 1992
18. Alter HJ: Chronic consequences of non-A, non-B hepatitis, in Current Perspective in Hepatology, edited by Seeff LB, Lewis JH. New York, Plenum, 1989, pp. 83-97
19. Kiyosawa K, Akahane Y, Nagata A, Koike Y, Furata S: The significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sang 43:45-52, 1982
20. Seeff LB, Buskell-Bales Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327:1906-1911, 1992
21. Brillanti S, Gaiani S, Migiloli M, et al.: Persistent hepatitis C viraemia without liver disease. Lancet 341:464-465, 1993
22. Caldwell Sh, Li X, Rourk RM, et al.: Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 86:1219-1223, 1991
23. Lin HH, Huang CC, Sheen IS, Lin DY, et al.: Prevalence of antibodies to hepatitis C virus in the hemodialysis unit. Am J Nephrol 11: 192-194, 1991
24. Hayashi J, Nakashima K, Kajiyama W, Noguchi A, et al.: Prevalence of antibody to hepatitis C in hemodialysis patients. Am J Epidemiol 134:651-657, 1991
25. Chan TM, Lok ASF, Cheng IKP, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology 17:5-8, 1993
26. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 112:958-960, 1990
27. Giammoria U, DeMeo F, Acitelli S, Tancredi M, Daniele M, et al.: HCV infection in HD patients: Incidence and correlation with dialytic age. Nephron 61:335-336, 1992
28. Fujiyama S, Kawano S, Sato S, Tonaka M, et al.: Prevalence of hepatitis C virus antibodies in hemodialysis patients and dialysis staff. Hepato-Gastroenterol 39:161-165, 1992
29. Martin P, Brezina M, Dixit V, DiNello R et al.: Acquisition of hepatitis C by hemodialysis patients. Hepatology 18:93A, 1993
30. Allander T, Medin C, Jacobson SH, Grillner L, et al.: Hepatitis C transmission in a hemodialysis unit: Molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 43:415-419, 1994
31. Corcoran GD, Brink NS, Millar CGM, Garson JA, et al.: Hepatitis C virus infection in haemodialysis patients: A clinical and virological study. J Infect 28:279-285, 1994
32. Chan TM, Lok ASF, Cheng IKP: Hepatitis C in renal transplant recipients. Transplantation 52:810-813, 1991
33. Simon N, Courouce AM, Lemorrec N, Trepo C, Ducamp S: A twelve year natural history of hepatitis C virus infection in hemodialysis patients. Kidney Int 46:504-511, 1994
34. Chiaramonte S, Tagger A, Ribero ML, Grossi A, Milan M, LaGreca G: Prevention of viral hepatitis in dialysis units: Isolation and technical management of dialysis. Nephron 61:287-289, 1992
35. Jadoul M: Should hemodialysis patients with hepatitis C virus antibodies be isolated? Sem Dialysis 8:1-3, 1995
36. Jadoul M, Cornu C, van Ypersele de Strihou C, and the UCLA collaborative group: Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 44:1322-1326, 1993
37. MMWR Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B and other blood-borne pathogens in health-care settings. JAMA 260:462-465, 1988
38. Parfrey PS, Farge D, Forbes RDC, Dandavino R, Kenick S, Guttman RD: Chronic hepatitis in end-stage renal disease: Comparison of HBsAg-negative and HBsAg-positive patients. Kidney Int 28:959-967, 1985
39. Caramelo C, Ortiz A, Aquilera B, Porres JC, et al.: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22:822-828, 1993
40. Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J: Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation 51:396-400, 1991
41. Chan TM, Lok ASF, Cheng IKP, Chan RT: A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 104:862-868, 1993
42. Pol S, Legendre C, Saltiel C, Carnot F, Brechot C, et al.: Hepatitis C virus in kidney recipients: epidemiology and impact on renal transplantation. J Hepatol 15:202-206, 1992
43. Chan TM, Wu PC, Lau JYN, Lai CL, Lok ASF, Cheng IKP: Clinicopathologic features of hepatitis C virus in renal allograft recipients. Transplantation 58:996-1000, 1994
44. Rao KV, Kasiske BL, Anderson WR: Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 94:241-250, 1993
45. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 331:365-376, 1994
46. DeMitri MS, Poussin K, Baccarini P, et al.: Selective persistence of HCV genotype 1b in liver cancers developing without cirrhosis [abstract]. J Hepatol (Suppl 1):S17, 1994
47. Lau JYN, Davis GL, Brunson ME, et al.: Hepatitis C infection in kidney transplant recipients. Hepatology 18:1027-1031, 1993
48. Fritsche C, Brandes JC, Delaney SR, et al.: Hepatitis C is a poor prognostic indicator in black kidney transplant recipients. Transplantation 55:1283-1287, 1993
49. Roth D, Zucker K, Cirocco R, et al.: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 45:238-244, 1994
50. Roth D, Fernandez JA, Babischkin S, DeMattos A, et al.: Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 117:470-475, 1992
51. Pereira BJG, Milford EL, Kirkman RL, et al.: Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 327:910-915, 1992
52. Pereira BJG, Wright TL, Schmid CH, Bryon CF, et al.: Screening and confirmatory testing of cadaver organ donors for hepatitis C virus: A US National Collaborative Study. Kidney Int 46:886-892, 1994
53. Ho M: Hepatitis C virus: Another agent transmitted by transplanted organs. N Engl J Med 325:507-509, 1991
54. King PD: Renal transplantation [letter]. N Engl J Med 331:1719, 1994
55. Sanchez-Tapias JM, Rodes J: Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet 345:469-470, 1995
56. Oldach D, Constantine N, Schweitzer E, Weir M, et al.: Clinical and virologic outcomes in hepatitis C virus infected renal transplant recipients. [abstract] Program and Abstracts of the Fourteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, 1995, p. 98
57. Farci P, Alter HJ, Govindarajan S, et al.: Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135-140, 1992
58. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325:454-460, 1991
59. Pirsch JD, Heisey D, D'Alessandro AM, Knechtle SJ, Sollinger HW, Beizer FO: Transplantation of hepatitis C kidneys: Defining the risks. Program and Abstracts of the Fourteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, 1995, p. 98
60. DiBisceglie AM, Martin P, Kassiandes C, et al.: Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
61. Ellis ME, Alfurayh O, Halim MA, et al.: Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 18:210-216, 1993
62. Cohen GA, Goffinet JA, Donabedian RK, Conn HO: Observations on decreased serum glutamic oxalacetic transaminase activity in azotemic patients. Ann Intern Med 84:275-280, 1976
63. Tsubota A, Chayama K, Ikeda K, et al.: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994
64. Olynyk JK, Reddy KR, Di Bisceglie AM, et al.: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108:1104-1009, 1995
65. Roth D, Zucker K, Cirocco R, Burke G, Esquenazi V, Miller J: Prospective, longitudinal studies of hepatitis C virus infection in renal allograft recipients. [abstract]. Program and Abstracts of the Fourteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, 1995, p. 98
66. Davis GL: Hepatitis C: Therapy, in AASLD Postgraduate Course - Hepatitis A through F: An Update, Chicago, November 11-12, p. 247-256
67. Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
68. Weimar W, Kramer P, Bijnen AB, et al.: The incidence of cytomegalo- and herpes simplex virus infections in renal transplant recipients treated with high dose recombinant leucocyte interferon: a controlled study. Scand J Urol Nephrol S92:37-39, 1985
69. Hirsch MS, Schooley RT, Cosimi AB, et al.: Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med 308:1489-1493, 1983
70. Rhodes J, Jones DH, Bleehen NM: Increased expression of human monocyte HLA-DR antigens and Fc receptors in response to human interferon in vivo. Clin Exp Immunol 53:739-743, 1983
71. Gisler RH, Lindhal P, Gresser J: Effects of interferon on antibody synthesis in vitro. J Immunol 113:438-440, 1974
72. Thervet E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H: Low dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 58:625-628, 1994
73. Rao VK, Anderson WR: Clinical and histological outcome following interferon treatment of chronic viral hepatitis, in uremic patients, before and after renal transplantation. [abstract]. Program and Abstracts of the Fourteenth Annual Meeting of the American Society of Transplant Physicians, Chicago, 1995, p. 99
74. Camps J, Garcia N, Riezu-Boj JI, Civiera MP, Prieto J: Ribavirin in the treatment of chronic hepatitis C unresponsive to alpha interferon. J Hepatol 19:408-412, 1993